DOAC vs Warfarin in CVT Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
Stroke 2022 Feb 10;[EPub Ahead of Print], S Yaghi, L Shu, E Bakradze, S Salehi Omran, JA Giles, JY Amar, N Henninger, M Elnazeir, AL Liberman, K Moncrieffe, J Lu, R Sharma, Y Cheng, AS Zubair, AN Simpkins, GT Li, JC Kung, D Perez, M Heldner, A Scutelnic, D Seiffge, B Siepen, A Rothstein, O Khazaal, D Do, SA Kasab, LA Rahman, EA Mistry, D Kerrigan, H Lafever, TN Nguyen, P Klein, H Aparicio, J Frontera, L Kuohn, S Agarwal, C Stretz, N Kala, S El Jamal, A Chang, S Cutting, H Xiao, A de Havenon, V Muddasani, T Wu, D Wilson, A Nouh, SD Asad, A Qureshi, J Moore, P Khatri, Y Aziz, B Casteigne, M Khan, Y Cheng, B Mac Grory, M Weiss, D Ryan, MC Vedovati, M Paciaroni, JE Siegler, S Kamen, S Yu, CR Leon Guerrero, E Atallah, GM De Marchis, A Brehm, T Dittrich, M Psychogios, R Alvarado-Dyer, T Kass-Hout, S Prabhakaran, T Honda, DS Liebeskind, K FurieFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.